Corrigendum to “TRIAL-based combination therapies in cancers” [Int. Immunopharmacol. 138 (2024) 112570]
International Immunopharmacology · 2026-08 · 182 · 116752
DOI: 10.1016/j.intimp.2026.116752 ↗Kurz gefasst
Korrektur in der Zeitschrift International Immunopharmacology, 2026-08. Verfasst von Qiumin Deng und 5 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Tumor Molecular Biology and State Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Life and Heal….
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- MOE Key Laboratory of Tumor Molecular Biology and State Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan Universi…
- Guangzhou Key Laboratory of Metabolic Diseases and Reproductive Health, Guangdong-Hong Kong Metabolism & Reproduction Joint Laboratory, Reproductive Medicine Center, Guangdong Second Provincial General Hospital, Guangzh…
Zitieren
APA
Deng, Q., Chen, L., Zhang, G., Liu, L., Luo, S. M., & Gao, X. (2026). Corrigendum to “TRIAL-based combination therapies in cancers” [Int. Immunopharmacol. 138 (2024) 112570]. International Immunopharmacology, 182, 116752. https://doi.org/10.1016/j.intimp.2026.116752
Vancouver
Deng Q, Chen L, Zhang G, Liu L, Luo SM, Gao X. Corrigendum to “TRIAL-based combination therapies in cancers” [Int. Immunopharmacol. 138 (2024) 112570]. International Immunopharmacology. 2026;182:116752. doi:10.1016/j.intimp.2026.116752
BibTeX
@article{Deng2026,
author = {Deng, Qiumin and Chen, Luxuan and Zhang, Gui and Liu, Langxia and Luo, Shi-Ming and Gao, Xuejuan},
title = {Corrigendum to “TRIAL-based combination therapies in cancers” [Int. Immunopharmacol. 138 (2024) 112570]},
journal = {International Immunopharmacology},
year = {2026},
volume = {182},
pages = {116752},
doi = {10.1016/j.intimp.2026.116752}
}
EUVIMED